GlassScriptPhysician profile
Michael Kornberg
NPI 1063742856
$32,932.88
in general payments reported to CMS, 2019-2025
7 companies · $99.76 in 2025
The $99.76 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,874 · 2020: $7,319 · 2021: $4,296 · 2022: $6,743 · 2023: $958 · 2024: $6,643 · 2025: $99.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,590 · Travel and Lodging: $576 · Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,590.00 |
| Travel and Lodging | $575.96 |
| Food and Beverage | $534.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $14,836.53 | 2019-2022 | |
| Genentech USA, INC. | $12,742.72 | 2022-2024 | Ocrevus |
| Tg Therapeutics, INC. | $3,600.00 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $1,596.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $60.60 | 2025 | Jornay Pm |
| Genentech, INC. | $59.60 | 2023-2025 | Ocrevus, Enspryng |
| Genzyme Corporation | $37.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kornberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.